Zydus Cadila has received tentative approval from the USFDA to market Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg (US RLD: TRuvADA Tablets). Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are used with
other HIV medications to help control HIV infection. This product is a combination of two different drugs: Emtricitabine and Tenofovir Disoproxil Fumarate and helps to decrease the amount of HIV in the body so that the immune system can work better.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 312 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
